Home
/
X4 Pharmaceuticals, Inc
/
Financials
/
Quarterly
X4 Pharmaceuticals, Inc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that X4 Pharmaceuticals, Inc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.57M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$1.74M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$900.0K
May 1, 2025
Q3
2025
Sep 30, 2024
$560.0K
Nov 5, 2025
Q2
2025
Jun 30, 2024
$563.0K
Aug 8, 2025
Q3
2024
Sep 30, 2023
$0
Nov 13, 2024
Q2
2024
Jun 30, 2023
$0
Aug 8, 2024
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.77M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$1.97M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$28.81M
May 1, 2025
Q3
2025
Sep 30, 2024
$560.0K
Nov 5, 2025
Q2
2025
Jun 30, 2024
$563.0K
Aug 8, 2025
Q1
2025
Mar 31, 2024
$0
May 1, 2025
Q3
2021
Sep 30, 2021
$0
Nov 4, 2021
Q2
2021
Jun 30, 2021
$0
Aug 3, 2021
Q1
2021
Mar 31, 2021
$0
May 6, 2021
Q3
2021
Sep 30, 2020
$0
Nov 4, 2021
Q2
2021
Jun 30, 2020
$0
Aug 3, 2021
Q1
2021
Mar 31, 2020
$3.00M
May 6, 2021
Q3
2020
Sep 30, 2019
$0
Nov 5, 2020
Q2
2020
Jun 30, 2019
$0
Aug 4, 2020
Q1
2020
Mar 31, 2019
$0
May 7, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($29.82M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($25.74M)
Aug 8, 2025
Q3
2025
Jun 30, 2025
($25.74M)
Nov 5, 2025
Q3
2025
Mar 31, 2025
$282.0K
Nov 5, 2025
Q2
2025
Mar 31, 2025
$282.0K
Aug 8, 2025
Q1
2025
Mar 31, 2025
$282.0K
May 1, 2025
Q3
2025
Sep 30, 2024
($36.70M)
Nov 5, 2025
Q3
2025
Jun 30, 2024
$90.83M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$90.83M
Aug 8, 2025
Q2
2025
Mar 31, 2024
($51.77M)
Aug 8, 2025
Q3
2025
Mar 31, 2024
($51.77M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($51.77M)
May 1, 2025
Q3
2024
Sep 30, 2023
($2.31M)
Nov 13, 2024
Q3
2024
Jun 30, 2023
($55.71M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($55.71M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($24.02M)
May 7, 2024
Q2
2024
Mar 31, 2023
($24.02M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($24.02M)
Nov 13, 2024
Q3
2023
Sep 30, 2022
($21.59M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($21.21M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($27.51M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($26.23M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($9.44M)
May 1, 2025
Q3
2025
Sep 30, 2024
($34.50M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
$71.10M
Aug 8, 2025
Q1
2025
Mar 31, 2024
($37.29M)
May 1, 2025
Q3
2024
Sep 30, 2023
($27.21M)
Nov 13, 2024
Q3
2023
Jun 30, 2023
($25.81M)
Aug 10, 2023
Q2
2024
Jun 30, 2023
($25.81M)
Aug 8, 2024
Q3
2022
Mar 31, 2023
($29.30M)
May 4, 2023
Q1
2024
Mar 31, 2023
($29.30M)
May 7, 2024
Q3
2023
Sep 30, 2022
($20.15M)
Nov 9, 2023
Q2
2022
Jun 30, 2022
($20.57M)
Aug 4, 2022
Q3
2023
Jun 30, 2022
($20.57M)
Aug 10, 2023
Q1
2022
Mar 31, 2022
($21.27M)
May 12, 2022
Q3
2022
Mar 31, 2022
($21.27M)
May 4, 2023
Q3
2022
Sep 30, 2021
($19.12M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($19.00M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($17.94M)
May 12, 2022
Q3
2021
Sep 30, 2020
($16.98M)
Nov 4, 2021